Financial Performance - The company's operating revenue for Q1 2023 was ¥1,301,021,684.04, a decrease of 31.90% compared to ¥1,910,323,745.74 in the same period last year[3]. - Net profit attributable to shareholders was ¥66,540,023.25, down 71.68% from ¥234,943,371.65 year-on-year[3]. - The net cash flow from operating activities was negative at ¥213,979,198.80, a significant decline of 15,418.93% compared to the previous year[3]. - Basic and diluted earnings per share were both ¥0.0453, reflecting a decrease of 71.71% from ¥0.1601 in the same period last year[3]. - Gross profit for the current period was RMB 454.0 million, down from RMB 579.2 million year-on-year, with a gross margin of 34.9%, up from 30.3%[12]. - Operating profit decreased by 74.02% to RMB 73.6 million, primarily due to a reduction in gross profit[9]. - The total comprehensive income for the current period is CNY 61,856,551.06, a decrease from CNY 230,706,330.71 in the previous period[32]. Assets and Liabilities - Total assets at the end of the reporting period were ¥20,623,022,731.91, a decrease of 0.92% from ¥20,814,206,782.52 at the end of the previous year[3]. - Total liabilities increased from CNY 8,406,564,448.47 to CNY 8,435,034,680.42, with an adjustment of CNY 28,470,231.95[24]. - Total assets amount to RMB 20,623,022,731.91, down from RMB 20,814,206,782.52, indicating a decrease of 0.9%[29]. - Total liabilities decreased to RMB 8,151,172,088.52 from RMB 8,406,564,448.47, reflecting a reduction of 3.0%[29]. - Non-current liabilities increased to RMB 3,016,772,193.42 from RMB 2,830,768,147.44, representing a growth of 6.6%[29]. Cash Flow - The company experienced a significant increase in cash flow from investment activities, reporting a net cash inflow of RMB 795.7 million, compared to a net outflow of RMB 88.0 million in the same period last year, representing a 1,003.94% increase[10]. - Cash inflow from operating activities is CNY 1,936,382,607.31, a slight decrease from CNY 1,964,042,020.61 in the previous period[34]. - Cash outflow from operating activities totals CNY 2,150,361,806.11, compared to CNY 1,965,420,847.89 in the previous period[35]. - Net cash flow from investment activities is CNY 795,650,734.04, a significant improvement from CNY -88,020,516.24 in the previous period[36]. - Net cash flow from operating activities is negative at CNY -213,979,198.80, compared to CNY -1,378,827.28 in the previous period[35]. Market and Sales Strategy - The company’s heparin sodium product sales volume and market share have rapidly increased over the past five years, becoming a key revenue growth driver[11]. - The company plans to strengthen its sales layout in Europe, where it holds a top two market share position, and will continue to expand its presence in untapped markets[13]. - The company is actively pursuing diversified marketing strategies and expanding sales territories to overcome current challenges[14]. - The company aims to optimize its supply chain management and resource distribution to support the expansion of its main business[11]. - The company received FDA approval for its heparin sodium injection, allowing for self-marketing in the U.S. market, marking a significant breakthrough[12]. Shareholder Information - The top ten shareholders hold significant stakes, with Shenzhen Lerun Technology Co., Ltd. owning 32.31% and Urumqi Jintian Investment Partnership holding 27.81%[18]. - The top ten shareholders include Shenzhen Le Ren Technology Co., holding 474,029,899 shares, and Urumqi Jintian Equity Investment Partnership, holding 408,041,280 shares, indicating strong institutional support[19]. Research and Development - Research and development expenses for the current period are RMB 26,514,765.57, an increase of 27.1% compared to RMB 20,883,937.48 in the previous period[30]. - The CDMO business is driven by Cytovance Biologics, Inc. and SPL Acquisition Corp., focusing on integrating R&D resources and enhancing customer collaboration[15]. Strategic Collaborations - The company entered a licensing agreement with Youhua Biotech for the commercialization of Oregovomab in Taiwan, enhancing its strategic partnerships in the Greater China region[20]. - The company’s subsidiary Tian Dao America signed a distribution agreement with Zhengda Tianqing for the commercialization of Fosaprepitant in the US, marking a significant step in its overseas marketing efforts[20].
海普瑞(09989) - 2023 Q1 - 季度业绩